Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia

E-ISSN： 1097-0142|119|22|4036-4043

ISSN： 0008-543x

Source： CANCER, Vol.119, Iss.22, 2013-11, pp. : 4036-4043

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gemtuzumab Ozogamicin (Mylotarg^®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 269-272

Karger

Access to resources Recommend Favorite

Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials

Oncology Research and Treatment, Vol. 30, Iss. 12, 2007-11 ,pp. : 657-662

Karger

Access to resources Recommend Favorite

Minimal residual disease as biomarker for optimal biologic dosing of ARA‐C in patients with acute myeloid leukemia

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 125-131

John Wiley & Sons Inc

Access to resources Recommend Favorite

Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia: Current Status and Challenges

Acta Haematologica, Vol. 112, Iss. 1-2, 2004-06 ,pp. : 34-39

Karger

Access to resources Recommend Favorite

Pilot Study of Gemtuzumab Ozogamicin (GO), Fludarabine, Cytarabine and Idarubicin Combined Regimen (GO-FLAI) as First-Line Induction Therapy plus GO Alone as Consolidation Therapy for Elderly Acute Myeloid Leukemia Patients

Acta Haematologica, Vol. 118, Iss. 1, 2007-03 ,pp. : 7-9

Karger

Access to resources Recommend Favorite